Alzheon announced the launch of the company, the securing of initial private financing, and the signing of an exclusive license agreement to a novel clinical drug candidate for Alzheimer’s disease, a family of analogs, and a drug development platform of chemotypes and clinical datasets developed by BELLUS Health of Quebec, Canada.
Netherland-based injectable drug delivery products producer InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan (AGN), to develop new medicines for ophthalmic diseases.
Adimab and Innovent have collaborated to discover, develop and commercialise an antibody-based therapeutic, using Adimab antibody discovery and optimization platform, against a selected specific target.
Takeda Pharmaceutical Company has announced the availability of NESINA (alogliptin) and fixed-dose combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) by prescription in the US.
Adimab signed a multi-target discovery agreement with Celgene Corporation, pursuant to which, Adimab will use its proprietary discovery and optimization platform to generate fully human antibodies against multiple targets.
Specialty pharmaceutical company Supernus Pharmaceuticals is set to launch once-daily extended release formulation of topiramate, Trokendi XR, to treat epilepsy following the final FDA approval.
Amedra Pharmaceuticals has re-launched a single-dose epinephrine auto-injector Adrenaclick for people with increased risk of anaphylaxis in both 0.15mg and 0.30mg strengths.